Published in Leukemia on April 09, 2012
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood (2015) 1.57
A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32
Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood (2014) 0.94
High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med (2013) 0.90
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. J Adolesc Young Adult Oncol (2015) 0.89
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood (2015) 0.87
Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL). Cancer Med (2016) 0.87
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol (2014) 0.81
Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther (2015) 0.79
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma (2015) 0.77
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS One (2015) 0.76
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma (2015) 0.75
Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res (2017) 0.75
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia. Onco Targets Ther (2017) 0.75
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother (2016) 0.75
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model. PLoS One (2016) 0.75
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Curr Hematol Malig Rep (2016) 0.75
L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo. Int J Environ Res Public Health (2016) 0.75
Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics (2017) 0.75
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med (2007) 6.98
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med (2004) 6.15
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum (2002) 2.99
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol (2000) 2.51
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer (2005) 2.02
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.91
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol (2004) 1.80
The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma (2007) 1.68
Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol (1993) 1.65
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol (2007) 1.56
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol (2004) 1.48
Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med (1986) 1.42
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37
In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res (1989) 1.37
Toxicity of E. coli L-asparaginase in man. Cancer (1970) 1.36
Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer (1998) 1.36
A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res (2009) 1.25
L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med (1971) 1.21
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia (2003) 1.18
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. Eur J Cancer (2006) 1.13
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood (1997) 1.05
Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer (1976) 1.00
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia (1998) 1.00
Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica (2008) 0.98
Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol (1986) 0.95
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods (2000) 0.94
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia (1998) 0.94
Immunological responses to L-asparaginase. J Clin Invest (1971) 0.94
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer (1982) 0.92
Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy. Eur J Pediatr (1989) 0.85
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell (1980) 8.10
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest (2001) 3.82
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron (2001) 3.56
High-throughput genotyping with single nucleotide polymorphisms. Genome Res (2001) 3.55
Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol (1993) 3.41
The mammalian sodium channel BNC1 is required for normal touch sensation. Nature (2000) 3.30
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Virus-assisted mapping of neural inputs to a feeding center in the hypothalamus. Science (2001) 2.98
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ (2000) 2.91
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
DNA electrochemical biosensor for the detection of short DNA sequences related to the human immunodeficiency virus. Anal Chem (1996) 2.45
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int (2001) 2.41
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Identification of a major keratinocyte cell envelope protein, loricrin. Cell (1990) 2.25
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
Heat flow and distribution during induction of general anesthesia. Anesthesiology (1995) 2.12
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Cyclin partners determine Pho85 protein kinase substrate specificity in vitro and in vivo: control of glycogen biosynthesis by Pcl8 and Pcl10. Mol Cell Biol (1998) 2.04
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 1.96
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia (1994) 1.87
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem (1997) 1.86
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A (2001) 1.83
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Neuropeptide FF and FMRFamide potentiate acid-evoked currents from sensory neurons and proton-gated DEG/ENaC channels. Neuron (2000) 1.81
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes (1994) 1.73
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
The effects of radiation on craniofacial skeletal growth: a quantitative study. Int J Pediatr Otorhinolaryngol (1998) 1.65
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Modeling immunotherapy of the tumor-immune interaction. J Math Biol (1998) 1.62
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol (2000) 1.57
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57